Second Cancer Risk After Radioiodine Therapy — An Honest Answer

Yes, slightly. Guideline bodies including the NCCN and ASTRO describe a small, real increase in the chance of a second cancer many years after radioiodine, and it rises with the total activity given over a lifetime. For a single standard dose after thyroid cancer surgery, the addition is small.

You will find pages that answer this with a flat “no, it is completely safe” and pages that answer it with a figure designed to frighten you. Both are wrong, in opposite directions. The truthful answer is that the risk exists, that it is small at the doses most people receive, and that it grows as cumulative activity grows.

Two areas come up most often in guideline discussions. The salivary glands concentrate iodine directly and sit in the path of the treatment. The blood and bone marrow receive a low-level whole-body exposure, and are discussed mainly in the context of high cumulative activity across several doses. Solid tumours elsewhere are discussed at the very long end of the timeline.

None of that is a reason to refuse a dose your team believes is needed. It is a reason to know your own numbers, which most survivors have never been told.

Radioiodine is administered at an NABH-accredited nuclear medicine partner centre; CION Cancer Clinics coordinates your treatment plan, your oncology team and your long-term follow-up throughout.

Small, in absolute terms. This page does not publish a single percentage, and that is deliberate. The honest figure depends on your cumulative activity, your age at treatment and how many years have passed. Guideline bodies including the NCCN and ASTRO, as of August 2026, describe a modest addition to a background risk everyone already carries.

Here is why published numbers feel so much bigger than they are. Almost all of them are quoted as relative risk, which describes how much a number moves. What you actually want is absolute risk, which describes how big that number was to begin with. A relative increase that sounds dramatic, applied to a background risk that is already small, still produces a small number of additional cases spread across a very large group of people over decades.

The second reason a single figure would mislead you is timing. Radiation-related second cancers are late effects. They are counted over twenty, thirty and forty year follow-up periods, so any number quoted without its time window is meaningless. This is the whole reason the question matters more for a survivor treated at thirty-two than at seventy-two — not because the biology differs, but because of how many years there are for a late effect to appear in.

And the third: the comparison most pages make is the wrong one. The choice in front of you was never radioiodine against nothing. It was radioiodine against leaving thyroid cancer tissue your team believes needs treating. That is the comparison your risk figure has to be weighed inside.

Ask your treating team to express your risk in absolute terms, over a stated number of years, for your cumulative dose. If a number is given to you without those three things attached, it cannot be interpreted.

Three groups, and they overlap. People who have had several doses, because cumulative activity is the strongest single driver. People treated young, because a late effect needs decades to appear and they have those decades. And people already carrying other risk, from tobacco, alcohol, earlier radiation or a known genetic predisposition.

Because it travels. Radioiodine is swallowed, absorbed and carried in the blood before thyroid tissue takes it up, and whatever is not taken up has to be cleared. Along that route, several tissues are briefly exposed to radiation they did not need, and radiation exposure carries a small long-term risk wherever it lands.

The salivary glands are the clearest example. They concentrate iodine, which is why dry mouth and altered taste are the effects survivors report most, and why they are also the tissues discussed first when late risk comes up. If you are living with those symptoms now, Taste Changes and Dry Mouth After Radioiodine covers what helps.

The bone marrow receives a low-level whole-body dose as the radioiodine circulates. At the activity used for a single ablation dose this is minor. It becomes a bigger part of the conversation when cumulative activity is high, which is one of the reasons a repeat dose is never automatic.

Reproductive tissue is exposed on the same principle, and is weighed separately for younger patients — explained in Radioiodine and Fertility in Men and Women.

This is also why radioiodine is not given to everyone with thyroid cancer, and why the amount given is kept to what the situation needs rather than the maximum that could be given. Where thyroid cancer tissue no longer takes up iodine at all, a dose would carry the exposure without the benefit, and teams turn to a different route — see When Thyroid Cancer Needs External Beam Radiation Instead.

• Living with dry mouth or altered taste since your dose? Those are the salivary effects discussed most often alongside long-term risk — see Taste Changes and Dry Mouth After Radioiodine.
• Being told a further dose is on the table? Cumulative activity is exactly where this page and that decision meet — see Will I Need a Second Dose of Radioiodine?
• Treated young and thinking about a family? Reproductive tissue is weighed on the same principle as everything else here — see Radioiodine and Fertility in Men and Women.
• Told your thyroid cancer no longer takes up iodine? Then the risk-benefit sum changes completely — see When Thyroid Cancer Needs External Beam Radiation Instead.
• Want the full picture of radiation care at CION? Our radiation therapy hub covers how external beam radiation, brachytherapy and radioiodine are each planned, delivered and coordinated with NABH-accredited partner centres.

Carrying this question on your own? Book a free consultation, or call 1800 202 8726 and have your dose history read with you.